These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19539254)

  • 1. Drug-eluting stents: safe but not sufficient.
    Vogel RA
    JACC Cardiovasc Interv; 2009 Jun; 2(6):513-4. PubMed ID: 19539254
    [No Abstract]   [Full Text] [Related]  

  • 2. Late clinical events after drug-eluting stents: the interplay between stent-related and natural history-driven events.
    Leon MB; Allocco DJ; Dawkins KD; Baim DS
    JACC Cardiovasc Interv; 2009 Jun; 2(6):504-12. PubMed ID: 19539253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion.
    Tcheng JE; Zidar DA
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1266-8. PubMed ID: 20129554
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Another small step for small vessels.
    Morrison DA
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravascular ultrasound optimization of drug-eluting stents: still not enough data.
    Leesar MA
    Catheter Cardiovasc Interv; 2010 Mar; 75(4):584-5. PubMed ID: 20333656
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug-eluting stents for ST-segment elevation myocardial infarction: treatment of choice or is discretion the better part of valor?
    Rihal CS
    JACC Cardiovasc Interv; 2008 Jun; 1(3):233-5. PubMed ID: 19463305
    [No Abstract]   [Full Text] [Related]  

  • 9. Left main and high-risk PCI: what, exactly, is it high risk for?
    Safian RD
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):952-3. PubMed ID: 21598347
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug-eluting stents: more dollars than sense?
    Garg S; Eisenberg MJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1188-9. PubMed ID: 20129544
    [No Abstract]   [Full Text] [Related]  

  • 11. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug eluting stents in CTOs: why not?
    Vetrovec GW
    Catheter Cardiovasc Interv; 2011 Feb; 77(3):333-4. PubMed ID: 21328678
    [No Abstract]   [Full Text] [Related]  

  • 13. Long stents as a risk factor for late stent thrombosis size does matter.
    Tommaso CL
    JACC Cardiovasc Interv; 2010 Apr; 3(4):390-1. PubMed ID: 20398865
    [No Abstract]   [Full Text] [Related]  

  • 14. Stent thrombosis--risk assessment and prevention.
    Motovska Z; Knot J; Widimsky P
    Cardiovasc Ther; 2010 Oct; 28(5):e92-100. PubMed ID: 20553282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "mini-crush" technique for managing bifurcation lesions.
    Kornowski R
    Catheter Cardiovasc Interv; 2009 Jul; 74(1):85-7. PubMed ID: 19530202
    [No Abstract]   [Full Text] [Related]  

  • 16. Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.
    Mukherjee D; Moliterno DJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1236-9. PubMed ID: 20129550
    [No Abstract]   [Full Text] [Related]  

  • 17. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of drug-eluting stents in women: a window of opportunity.
    Jacobs AK
    JACC Cardiovasc Interv; 2009 Jul; 2(7):611-3. PubMed ID: 19628182
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. My stent is better than your stent...Or is it?
    Bates ER; Menees DS
    JACC Cardiovasc Interv; 2011 May; 4(5):551-3. PubMed ID: 21596328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.